Advances in the Treatment of Bleeding Disorders

Bleeding disorder is a medical condition characterized by the improper functioning of blood clotting process called as coagulation. Body’s coagulation system is unable to form blood clots at the site of injury, at incisions made during surgery, trauma or menstruation which results in moderate to high levels of blood loss. Most of bleeding disorders are inherited. It is also acquired with some liver diseases, side effects of certain medications, low red blood cell count, and vitamin K deficiency. There are three main types of this condition: hemophilia, clotting factor deficiency, and Von Willebrand Disease (VWD). Treatment of bleeding disorder depends on the severity and type of disorder. Various treatment options are available for bleeding disorder such as replacement therapies which include clotting factor replacement, fresh frozen plasma transfusion, platelet transfusion, iron supplementation, and medication treatments.

Most of the bleeding disorders are inherited and are not completely curable. However, various treatments are available to control the symptoms. The global bleeding disorder market is expected to be driven by the increasing number of diagnosed patients with bleeding disorders across the globe, awareness about bleeding disorder among global population, and government initiatives in developed countries toward the establishment of wide network of diagnosis and treatment centers for bleeding disorders.

Download PDF Brochure, Click Here

Image Credit: NetDoctor

Bleeding disorder is a medical situation described by the despicable working of blood clotting procedure known as coagulation. Body’s coagulation framework can’t shape blood clumps at the site of damage or injury, at cuts made amid surgery, feminine cycle which results in large amounts of blood loss. Different treatment choices are available for bleeding disorders such as, substitution treatments which incorporate replacement of coagulating, iron supplementation and fresh frozen plasma and platelet transfusion.

According to the Hemophilia Federation of America, over 20,000 people are affected with hemophilia and 1% of population is suffering with Von Willebrand Disease (VWD). Asia Pacific is expected to witness exponential growth during the forecast period owing to emerging economies such as India and China. According to UNAIDS, there were an estimated 36.9 million people globally were living with HIV in 2017. Out of 36.9 million 1.8 million people became newly infected with HIV in 2017.

In Feb 2019, Roche to acquire Spark Therapeutics. Spark Therapeutics is a fully integrated, commercial company it is working in genetic diseases, including blindness, hemophilia, lysosomal storage disorders and neurodegenerative diseases.
In Feb 2019, FDA approves Cablivi®, Cablivi® is made by Sanofi. It is First medicine approval in the U.S. specifically for the treatment of a TTP, a rare blood-clotting disorder. Sanofi is a global biopharmaceutical company focused on human health. It will change market dynamics.

Few of the major competitors currently working in the bleeding disorders treatment market are Shire (U.S.), Baxter (U.S), CSL (U.S.), Alnylam Pharmaceuticals, Inc.(U.S), Bayer AG (Germany), Novo Nordisk A/S (Denmark), Pfizer Inc. (U.S.), Xenetic Biosciences, Inc. (U.S), Biogen (U.S.), Bristol-Myers Squibb Company (U.S), Octapharma (Switzerland), Sanofi (France), Amgen, Inc.(U.S), Bioverativ (U.S), Janssen Global Services, LLC (U.S), Cangene Corporation (Canada), and among others.

Source: The insight Partners